Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Head and Neck Cancers

15 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCHN0603

    04/28/2006

    Effect of PI3K Inhibition in HPV Infected Cell (deidentified)

    Basic Science

    VICCHN0529

    05/10/2005

    Novel Protein Regulator of Tumor Suppressor ARF & NF-kB (NIH/2 R01 DEO13173-05) (deidentified)

    Basic Science

    VICCHN0530

    04/08/2005

    Serum Biomarkers for Head & Neck Cancer (deidentified)

    Basic Science

    VICCHN0356

    02/04/2003

    Head and Neck Tumor Tissue Repository and Clinical Database

    Other

    VICCSUPP1517

    10/16/2015

    A Qualitative Study to Explore Patients' Experience of Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Evaluate Relevant Patient-Reported Outcome Measures for Clinical Trials

    Other

    VICCSUPP1530

    04/14/2015

    A Patient-Centered Outcomes Study of Patients with Recurrent Head and Neck Cancer

    Supportive Care

    VICCSUPP1529

    06/08/2015

    Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients

    Treatment

    VICCMD15110

    04/05/2016

    A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

    Treatment

    VICCHN1574

    03/21/2016

    A Randomized, Multicenter, Double-Blind Phase 2 Study of Palbociclib plus Cetuximab versus Cetuximab for the Treatment of Human Papillomavirus -Negative, Cetuximab-Naive Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck After Failure of One Prior Platinum-Containing Chemotherapy Regimen

    Treatment

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    VICCHN1575

    01/08/2016

    A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

    Treatment

    VICCPHI1598

    12/10/2015

    A Phase 1 Multi Arm Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 with seribantumab (MM-121), istiratumab (MM-141), or trametinib in biomarker-selected cancer patients

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    ECOGHNE3311

    08/29/2014

    Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

    Treatment

    ECOGHNE1305-M

    02/11/2009

    A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer


    Print this page for your doctor